Esperion Therapeutics (ESPR) Now Covered by Credit Suisse Group

Credit Suisse Group initiated coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Wednesday morning, MarketBeat reports. The firm issued an outperform rating and a $103.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the stock. UBS Group set a $88.00 target price on shares of Esperion Therapeutics and gave the company a buy rating in a report on Wednesday. Stifel Nicolaus set a $105.00 target price on shares of Esperion Therapeutics and gave the company a buy rating in a report on Monday. BidaskClub upgraded shares of Esperion Therapeutics from a buy rating to a strong-buy rating in a report on Saturday, January 13th. Bank of America upgraded shares of Esperion Therapeutics from a neutral rating to a buy rating and set a $76.00 target price for the company in a report on Friday, January 5th. Finally, Needham & Company LLC raised shares of Esperion Therapeutics from a buy rating to a strong-buy rating and raised their price target for the company from $72.00 to $81.00 in a research report on Thursday, December 14th. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $72.85.

Esperion Therapeutics (NASDAQ ESPR) traded down $0.88 during mid-day trading on Wednesday, hitting $74.96. 566,864 shares of the stock traded hands, compared to its average volume of 586,576. Esperion Therapeutics has a 1 year low of $10.71 and a 1 year high of $76.17. The stock has a market capitalization of $1,930.00, a price-to-earnings ratio of -10.93 and a beta of 2.73.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the previous year, the firm posted ($0.77) EPS. equities research analysts anticipate that Esperion Therapeutics will post -7.36 earnings per share for the current year.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the sale, the director now owns 2,472 shares of the company’s stock, valued at approximately $133,117.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 32.50% of the company’s stock.

A number of large investors have recently bought and sold shares of ESPR. Meditor Group Ltd grew its position in Esperion Therapeutics by 305.5% in the 3rd quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after purchasing an additional 1,728,935 shares during the period. State Street Corp grew its position in Esperion Therapeutics by 264.6% in the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock worth $69,721,000 after purchasing an additional 1,093,292 shares during the period. Discovery Capital Management LLC CT grew its position in Esperion Therapeutics by 152.9% in the 2nd quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock worth $44,663,000 after purchasing an additional 583,529 shares during the period. Caisse DE Depot ET Placement DU Quebec bought a new stake in Esperion Therapeutics in the 3rd quarter worth approximately $12,583,000. Finally, BNP Paribas Arbitrage SA grew its position in Esperion Therapeutics by 12,603.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 201,476 shares of the biopharmaceutical company’s stock worth $10,098,000 after purchasing an additional 199,890 shares during the period. 92.35% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/19/esperion-therapeutics-espr-now-covered-by-credit-suisse-group.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply